Table 1

Patient characteristics

Number of patients
Sex  
 Male 5 (42%) 
 Female 7 (58%) 
Age, median (range), y 66 (48-79) 
Background bowel function  
 Normal 5 (42%) 
 Lifelong intermittent loose stool 3 (25%) 
 Other GI history (not diarrhea) 4 (33%) 
Time to deterioration of bowel function following lenalidomide commencement, median (range), mo 6 (1-15) 
Dose of lenalidomide  
 25 mg 5 (41%) 
 10-15 mg 7 (58%) 
Symptoms  
 Diarrhea* 12 (100%) 
 Urgency 11 (92%) 
 Fecal incontinence 7 (58%) 
 Abdominal cramps 5 (42%) 
Number of patients
Sex  
 Male 5 (42%) 
 Female 7 (58%) 
Age, median (range), y 66 (48-79) 
Background bowel function  
 Normal 5 (42%) 
 Lifelong intermittent loose stool 3 (25%) 
 Other GI history (not diarrhea) 4 (33%) 
Time to deterioration of bowel function following lenalidomide commencement, median (range), mo 6 (1-15) 
Dose of lenalidomide  
 25 mg 5 (41%) 
 10-15 mg 7 (58%) 
Symptoms  
 Diarrhea* 12 (100%) 
 Urgency 11 (92%) 
 Fecal incontinence 7 (58%) 
 Abdominal cramps 5 (42%) 

Data are presented as n (%) of patients unless indicated otherwise.

*

Defined by Bristol Stool Chart (BSC) score 6 or 7. Median stool frequency: 6 episodes per day (range, 1-10).

Close Modal

or Create an Account

Close Modal
Close Modal